Latest filings (excl ownership)
S-8
Registration of securities for employees
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
22 Mar 24
8-K
Humacyte, Inc. Announces Proposed Public Offering of Common Stock
4 Mar 24
424B5
Prospectus supplement for primary offering
1 Mar 24
424B5
Prospectus supplement for primary offering
29 Feb 24
8-K
Other Events
29 Feb 24
8-K
Human Acellular Vessel™ (HAV™) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma
9 Feb 24
8-K
Other Events
12 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Humacyte Third Quarter 2023 Financial Results and Business Update
9 Nov 23
8-K
Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma
12 Sep 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
8-K
Humacyte Second Quarter 2023 Financial Results and Business Update
14 Aug 23
8-K
Humacyte Completes Enrollment in Phase 2/3 Trial of
26 Jul 23
424B3
Prospectus supplement
22 Jun 23
EFFECT
Notice of effectiveness
22 Jun 23
CORRESP
Correspondence with SEC
16 Jun 23
UPLOAD
Letter from SEC
15 Jun 23
S-3
Shelf registration
9 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
8 Jun 23
10-Q
2023 Q1
Quarterly report
12 May 23
8-K
Humacyte First Quarter 2023 Financial Results and Business Update
12 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
10-K
2022 FY
Annual report
24 Mar 23
8-K
Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update
24 Mar 23
8-K
Regulation FD Disclosure
13 Mar 23
8-K
Amendments to Articles of Incorporation or Bylaws
12 Dec 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Humacyte Third Quarter 2022 Financial Results and Business Update
10 Nov 22
8-K
Humacyte Expands Board of Directors and Leadership Team with New Appointments
20 Sep 22
EFFECT
Notice of effectiveness
15 Sep 22
POS AM
Prospectus update (post-effective amendment)
12 Sep 22
EFFECT
Notice of effectiveness
12 Sep 22
EFFECT
Notice of effectiveness
12 Sep 22
424B3
Prospectus supplement
9 Sep 22
424B3
Prospectus supplement
9 Sep 22
CORRESP
Correspondence with SEC
7 Sep 22
CORRESP
Correspondence with SEC
7 Sep 22
Latest ownership filings
SC 13D/A
Niklason Laura E
8 Mar 24
SC 13D/A
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/
7 Mar 24
4
William John Scheessele
12 Dec 23
4
Heather Ledbetter Prichard
12 Dec 23
4
Shamik J Parikh
12 Dec 23
4
Yang Cao
12 Dec 23
4
Dale A. Sander
12 Dec 23
4
Brady W Dougan
12 Dec 23
4
Laura E Niklason
12 Dec 23
SC 13D/A
FRESENIUS MEDICAL CARE HOLDINGS INC /NY/
1 Dec 23
4
Max N. Wallace
21 Nov 23
4
Brady W Dougan
10 Oct 23
4
Laura E Niklason
10 Oct 23
SC 13D/A
Niklason Laura E
15 Sep 23
4
Laura E Niklason
15 Sep 23
4
Brady W Dougan
15 Sep 23
SC 13D/A
Niklason Laura E
22 Aug 23
4
Laura E Niklason
21 Aug 23
4
Brady W Dougan
21 Aug 23
4
Change in insider ownership
21 Aug 23
144
Notice of proposed sale of securities
17 Aug 23
4
Emery N. Brown
16 Jun 23
4
Max N. Wallace
16 Jun 23
4
Charles Bruce Green
16 Jun 23
4
Brady W Dougan
16 Jun 23
4
Kathleen Sebelius
16 Jun 23
4
Michael T. Constantino
16 Jun 23
4
Todd Pope
16 Jun 23
4
Gordon M Binder
16 Jun 23
4
Rajiv Shukla
16 Jun 23
4
Susan Richards Windham-Bannister
16 Jun 23
4
Diane Seimetz
16 Jun 23
4
Laura E Niklason
16 Jun 23
4
Laura E Niklason
16 Jun 23
4
Brady W Dougan
16 Jun 23
4
Change in insider ownership
16 Jun 23
SC 13D/A
Niklason Laura E
15 Jun 23
4
Laura E Niklason
15 Jun 23
4
Brady W Dougan
15 Jun 23
4
Change in insider ownership
15 Jun 23